About 10%-20% of people with multiple sclerosis (MS) receive baclofen to control their spasticity, but up to half of patients stop the medication in the first six months, a large Swedish population-based study shows.
The high rates of discontinuation suggest baclofen has “a low success rate of treating spasticity and demonstrates an unmet need of tolerated, effective spasticity treatments,” researchers wrote.
The study, “Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study,” was published in the Journal of Neurology, Neurosurgery & Psychiatry.
Read more at: https://multiplesclerosisnewstoday.com/more-than-half-ms-patients-discontinue-baclofen-study/
